Severity
Moderate
FDA Drug recall · Reported August 8, 2012
Presence of Particulate Matter: This product is being recalled due to the discovery of particles in the stability samples and retain samples.
West-ward Pharmaceutical Corp. recalled Fosphenytoin Sodium Injection, USP, 100 mg PE per 2 mL (50 mg PE per mL), 2 mL Single Dos… - a moderate-severity action.
Fosphenytoin Sodium Injection, USP, 100 mg PE per 2 mL (50 mg PE per mL), 2 mL Single Dos… was recalled by West-ward Pharmaceutical Corp. in August 8, 2012. Reason: Presence of Particulate Matter: This product is being recalled due to the discovery of particles in the stabi…. Check the official notice for the remedy. Verify recall #D-1437-2012 with the FDA Drug before acting.
The recall
West-ward Pharmaceutical Corp. issued this moderate-severity FDA Drug recall-Presence of Particulate Matter: This product is being recalled due to the discovery of particles in the stabi….
Sourced from official FDA Drug enforcement records. Verify recall #D-1437-2012 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-1437-2012) was formally reported on August 8, 2012, with the manufacturer initiating the action on April 13, 2012. It is classified under Moderate severity (Class II), with a current status of Terminated. West-ward Pharmaceutical Corp. is listed as the recalling firm, operating out of Eatontown, NJ. Federal records list the affected scope as a) 308,275 vials; b) 2,008,850 vials.
The documented reason for this recall is: Presence of Particulate Matter: This product is being recalled due to the discovery of particles in the stability samples and retain samples. Distribution data in the federal record shows the product reached: All lots were distributed throughout the US.. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified moderate severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Moderate
Affected scope
a) 308,275 vials; b) 2,008,850 vials
Related Recalls
6
5 from same agency
Fosphenytoin Sodium Injection, USP, 100 mg PE per 2 mL (50 mg PE per mL), 2 mL Single Dose Vial, packaged in 25-count x 2 mL Single Dose Vials per carton, Rx only, Mfd. By: Hikma Farmaceutica (Portugal), S.A.; Dist. By: West-Ward Pharmaceutical Corp., Eatontown, NJ 07724 USA under the labels a) NOVAPLUS (NDC 0143-9704-25), b) West-Ward (NDC 0143-9788-25).
Presence of Particulate Matter: This product is being recalled due to the discovery of particles in the stability samples and retain samples.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Moderate (Class II) |
| Status | Terminated |
| Recall number | D-1437-2012 |
| Date reported | August 8, 2012 |
| Date initiated | April 13, 2012 |
| Recalling firm | West-ward Pharmaceutical Corp. |
| Firm location | Eatontown, NJ |
| Affected scope | a) 308,275 vials; b) 2,008,850 vials |
| Distribution | All lots were distributed throughout the US. |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported August 8, 2012. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.